Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
They are currently licensed only for type 2 diabetes and obesity, and their use in Parkinson's is considered experimental and investigational within clinical trials
A GLP-1 receptor agonist, used in metabolic and glucose-signaling research
About $199/mo for compounded semaglutide and $349/mo for compounded tirzepatide in 2026, with flat pricing as the dose increases
This can indirectly support weight loss by reducing overeating and stabilizing energy levels throughout the day
US$ 27.51
US$ 28.55
US$ 21.79
